• Chao Yang, Qing Zhang, Chao Ma, Yong Huang, Hai-Xia Ding, Jun-Wei Lu, Jie Wang, Xiang Li, Ya-Hua Zhong, and Zhi-Qiang Li.
• Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
• Medicine (Baltimore). 2023 May 19; 102 (20): e33830e33830.

AbstractTumor treating fields (TTFields) is a novel approved modality for the treatment of glioblastoma (GBM) exhibiting a satisfactory effect. Although TTFields has shown considerable safety for the normal brain, dermatological adverse events (DAEs) often occur during therapy. However, studies focused on the identification and management of DAEs are rare. The clinical data and photos of skin lesions from 9 patients with GBM were retrospectively analyzed, and the types and grades of individual scalp dermatitis were evaluated based on the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0). Adherence and safety were also evaluated on the basis of the device monitoring data. Eight patients (88.9%) exhibited grade 1 or grade 2 CTCAE DAEs, all of whom were cured after interventions. The adherence was >90%, with no relevant safety events reported. Finally, a guideline for preventing DAEs in patients with GBM was proposed. The identification and management of TTFields-related DAEs is necessary and urgent in patients with GBM. Timely interventions of DAEs will help to improve the adherence and quality of life of patients, which ultimately improves prognosis. The proposed guideline for preventing DAEs in patients with GBM assists in the management of healthcare providers and may avoid dermatologic complications.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

37 keywords...

hide…